Crovalimab

6 trials 1 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

5 Completed trials

1 Sponsors

16 Countries

Phase III

Phase I (Other)

Phase I (FiH)

Phase III: 4 Phase I (Other): 1 Phase I (FiH): 1

Oversight events:

6 temporary halts across 1 trial

View oversight register →

Indications tested

Sickle cell disease 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 6

All trials

6 total

A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting

2023-505638-82-00 Phase III 6 countries F. Hoffmann-La Roche AG
A Study Evaluating the Efficacy and Safety of Crovalimab in Adult and Adolescent Patients with atypical Hemolytic Uremic Syndrome (aHUS) Ended

2023-505089-27-00 Phase III 7 countries F. Hoffmann-La Roche AG
A Study to Evaluate the Efficacy and Safety of Crovalimab versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemog… Ended

2023-506498-36-00 Phase III 9 countries F. Hoffmann-La Roche AG
A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemo… Ended

2023-506526-37-00 Phase III 13 countries F. Hoffmann-La Roche AG
A Study to Assess Safety, Effectiveness, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Patients with Paroxys… Ended

2023-506287-14-00 Phase I (FiH) 4 countries F. Hoffmann-La Roche AG
A Study Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso‑O… Ended

2022-502546-26-00 Phase I (Other) 4 countries F. Hoffmann-La Roche AG

Showing 1–6 of 6 trials

← All drugs A–Z